Fresenius - the health care group
The Fresenius Group consists of the following four business segments that are responsible for their own business operations worldwide: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed.
The Catalonian Online Hemodiafiltration Survival Study (ESHOL) published in February 2013 confirms Fresenius Medical Care’s conviction that every patient should be given the chance to benefit from hemodiafiltration (HDF) therapy with high volumes of substitution fluid (HighVolumeHDF). The primary outcome of the study was that HighVolumeHDF therapy significantly improves patient survival compared with conventional dialysis treatment.>>>
After setting new records for sales and earnings last year, Fresenius is expecting further increases in fiscal 2013. At the Annual General Meeting in Frankfurt today, Ulf Mark Schneider, CEO of Fresenius, confirmed the global health care group’s goal of exceeding €20 billion in sales this year.>>>
Fresenius Medical Care will simplify the company’s capital structure. At the annual general meeting in Frankfurt today, a large shareholder majority of 99.97% approved the mandatory conversion of preference shares into ordinary shares on a 1:1 basis, as recommended by the Management Board and the Supervisory Board.>>>
Ulf Mark Schneider, CEO of Fresenius, said: “Fresenius is off to an excellent start in 2013. We improved on last year’s outstanding sales and earnings and had the best first quarter in the Company’s history. Fresenius Kabi and Fresenius Helios recorded particularly strong growth. (...)”>>>
Fresenius Medical Care AG & Co. KGaA today announced its results for the first quarter of 2013. Net revenue for the first quarter of 2013 increased by 7% to $3,464 million (+7% at constant currency) compared to the first quarter of 2012.>>>